Latest database descriptions

The objectives of the POLA network for high-grade oligodendroglial tumours are threefold:
- To harmonise tumour diagnosis techniques through the systematic organisation of a double histological analysis of tumour samples and their molecular characterisation Therapeutic treatment harmonisation.
- Research development for rare tumours through the creation of a clinical database closely associated with the conservation of tumour samples and its accessibility to neuro-oncology research teams.
- Distribution of information and knowledge among health professionals, patients and those close to them.

General objective: to develop and expand the cohort and enteric neuropathy biological collection for patients with IBD and Parkinson's disease (PD).
Secondary objectives:
- Transcriptomic study of neuronal and glial plasticity;
- Study and classification of neuro-degenerative processes;
- Correlation of neuronal damage with clinical parameters and outlook.

General objective: To study and compare the effectiveness of different in vivo markers to predict cognitive decline in patients at risk of developing Alzheimer's disease through neuroimaging, neuropsychology and biology measures.

Secondary objectives: To study:
i) Deterioration in NORMA subjects, as well as SCI, MCI, AD and SAND patients compared with healthy subjects of the same age;
ii) Deterioration in E4 allele and apolipoprotein E (ApoE) carriers compared to non-carriers;
iii) Cerebral and cognitive changes during normal ageing;
iv) Progress and dynamics of different biomarkers during follow-up.
To study the links between different deterioration profiles (intra-modality comparison and correlation), as well as differences in inter-group progression profiles.

PSOBIOTEQ is a national multicentric prospective cohort of cutaneous psoriasis patients receiving systemic treatment (biotherapy or conventional treatment) for moderate to severe cutaneous psoriasis.

PSOBIOTEQ is the result of merging two studies that share the same study population but address different objectives: PSOBIO, developed by academic dermatologists and epidemiologists focusing on safety issues, and Pso-TEQ, developed by industrial teams at the request of the French Transparency Commission (Haute Autorité de Santé) that focuses on usage issues.

The exposure of interest is the biological therapy exposure: Infliximab, Adalimumab, Etanercept and Ustekinumab.

The general objective of PSOBIO is to assess the safety and efficacy of biotherapy in the treatment of cutaneous psoriasis "in real life" compared with conventional systemic therapy. However, Pso-TEQ has a descriptive objective concerning the usage methods of biological therapies "in real life" and the long-term benefits.